Sanofi CEO pledges deeper review of late-stage pipeline before Phase 3 moves

Sanofi's new chief executive, Belén Garijo, announced that the company will examine its late-stage pipeline more closely.

The goal is to ensure that data from Phase 2 (or Phase 1b, depending on the therapeutic area) justify the significant capital required for Phase 3 development.

A rigorous portfolio prioritization process is being put in place, though Garijo did not specify a target number of programs to discontinue.

The approach signals a more fact‑based, cautious stance on advancing candidates, aimed at protecting long‑term value for the company.